These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 19147760)
1. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Holzer AK; Katano K; Klomp LW; Howell SB Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465 [TBL] [Abstract][Full Text] [Related]
3. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Holzer AK; Howell SB Cancer Res; 2006 Nov; 66(22):10944-52. PubMed ID: 17108132 [TBL] [Abstract][Full Text] [Related]
4. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296 [TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
6. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Ivy KD; Kaplan JH Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413 [TBL] [Abstract][Full Text] [Related]
7. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Howell SB; Safaei R; Larson CA; Sailor MJ Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940 [TBL] [Abstract][Full Text] [Related]
8. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438 [TBL] [Abstract][Full Text] [Related]
10. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Blair BG; Larson CA; Safaei R; Howell SB Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135 [TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Shang X; Lin X; Manorek G; Howell SB Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666 [TBL] [Abstract][Full Text] [Related]
12. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Kuo MT; Fu S; Savaraj N; Chen HH Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276 [TBL] [Abstract][Full Text] [Related]
13. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. Guo Y; Smith K; Petris MJ J Biol Chem; 2004 Nov; 279(45):46393-9. PubMed ID: 15326162 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375 [TBL] [Abstract][Full Text] [Related]
16. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647 [TBL] [Abstract][Full Text] [Related]
17. EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. Wang X; Jiang P; Wang P; Yang CS; Wang X; Feng Q PLoS One; 2015; 10(4):e0125402. PubMed ID: 25927922 [TBL] [Abstract][Full Text] [Related]
18. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. Kalayda GV; Wagner CH; Jaehde U J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323 [TBL] [Abstract][Full Text] [Related]
19. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751 [TBL] [Abstract][Full Text] [Related]
20. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]